Isolated hypogonadotropic hypogonadism …

Edward Yang MD PhD

Developmental Malformations

Updated 01.19.2024
Released 05.19.1999
Expires For CME 01.19.2027

Isolated hypogonadotropic hypogonadism

Author: Edward Yang MD PhD

See Contributor Disclosures

Editor: Ganeshwaran H Mochida MD

Isolated hypogonadotropic hypogonadism

In This Article

Quick Link

Introduction

Overview

Isolated hypogonadotropic hypogonadism (IHH) refers to failed sexual development and reproductive function due to a congenital deficiency of gonadotropins. By definition, it excludes panhypopituitarism, causes of impaired function at the level of the gonads (hypergonadotropic hypogonadism or primary hypogonadism), and acquired causes of hypothalamic-pituitary dysfunction (eg, CNS tumor, brain injury). When coupled with impaired olfaction, isolated hypogonadotropic hypogonadism is known as Kallmann syndrome, but genetically defined causes of isolated hypogonadotropic hypogonadism commonly present with both normosmic and anosmic phenotypes, diminishing the usefulness of this distinction. Additionally, the genetics of isolated hypogonadotropic hypogonadism are extremely complex, reflecting a mixture of classic Mendelian inheritance patterns (X-linked, autosomal recessive, autosomal dominant), variable degrees of penetrance, and instances of oligogenic inheritance, with more than 25 genetically defined forms currently recognized. In this article, the author reviews the clinical manifestations, pathogenesis, genetics, epidemiology, diagnosis, and management of isolated hypogonadotropic hypogonadism.

Key points

	• Isolated hypogonadotropic hypogonadism refers to congenital deficiency of gonadotropins.
	• When occurring in combination with impaired olfactory function, isolated hypogonadotropic hypogonadism is known as Kallmann syndrome, which is defined as a subset of isolated hypogonadotropic hypogonadism for the purposes of this review.
	• The diagnosis may be suggested by the observation of micropenis or cryptorchidism in infancy or delayed onset of puberty in older patients. Because of the clinical overlap between constitutional delay in puberty and isolated hypogonadotropic hypogonadism, diagnosis can be challenging.
	• Affected individuals have variably deficient gonadal function and additional comorbidities related to the specific genetic etiology.
	• More than 25 genetic causes of isolated hypogonadotropic hypogonadism have been described. Although many genetic etiologies of isolated hypogonadotropic hypogonadism have classic Mendelian inheritance and full penetrance, several genetic etiologies have complex inheritance patterns that are not yet fully understood.

Historical note and terminology

Hypogonadism manifests as a failure of the major functions of gonads, namely the production of sex steroids and gametogenesis. The understanding of this condition has evolved with the basic science understanding of the hypothalamic-pituitary axis and the ability to probe it through diagnostic testing (06). Defects at the level of the gonads (eg, gonadotropin receptor deficiency, sex chromosome aneuploidy) characteristically demonstrate elevated gonadotropins (ie, follicle-stimulating hormone and luteinizing hormone), hypergonadotropic hypogonadism, whereas central deficiencies (eg, pituitary or hypothalamic defects) manifest as hypogonadotropic hypogonadism. Once imaging and laboratory investigations exclude those individuals with lesional or systemic causes of hypogonadotropic hypogonadism (eg, hemochromatosis, CNS tumor), a population of “idiopathic” or “isolated” hypogonadotropic hypogonadism patients can be defined (henceforth termed isolated hypogonadotropic hypogonadism or isolated hypogonadotropic hypogonadism). In practice, most of these patients demonstrate an inability to synthesize gonadotropin-releasing hormone (GnRH); therefore, some authors prefer the term isolated GnRH deficiency.

When isolated hypogonadotropic hypogonadism occurs in combination with anosmia or hyposmia, it is termed Kallmann syndrome. The condition was described by Kallmann and colleagues in 1944, although it was apparently recognized by other investigators as early as 1856 (38; 21; 10; 31). Given the unique X-linked inheritance and highly penetrant presentation for ANOS1-related Kallmann syndrome, the genetic elucidation of Kallmann syndrome provided the first genetic and mechanistic explanation for isolated hypogonadotropic hypogonadism (72). However, subsequent investigations have demonstrated that many genetic causes of isolated hypogonadotropic hypogonadism can present with both anosmic and normosmic forms (06). As a result, it is necessary to consider genetic causes of normosmic isolated hypogonadotropic hypogonadism and anosmic or hyposmic isolated hypogonadotropic hypogonadism (Kallmann syndrome) together when evaluating a patient for isolated hypogonadotropic hypogonadism.

Clinical manifestations

Presentation and course

A congenital deficiency in gonadotropin secretion is responsible for hypogonadism in isolated hypogonadotropic hypogonadism. This deficiency ranges from mild to severe. In mild isolated hypogonadotropic hypogonadism, some secondary sexual characteristics (eg, pubic hair) are often present due to adrenally sourced androgens, and especially mild forms of isolated hypogonadotropic hypogonadism can have preserved fertility (71; 76; 65). Spontaneous reversal of hypogonadism has been documented in some of these patients with mild isolated hypogonadotropic hypogonadism (23); in others, reversal may occur after hormonal therapy (69). In more severe forms, levels of luteinizing and follicle-stimulating hormones are low, sexual maturation is absent, and the patient is infertile. Diagnosing isolated hypogonadotropic hypogonadism is difficult before puberty and is traditionally done later when delayed sexual maturation becomes evident. However, abnormalities of male genitalia (ie, micropenis and cryptorchidism) can be detected in as many as 20% to 60% of male neonates with isolated hypogonadotropic hypogonadism (73).

In Kallmann syndrome, deficient olfaction accompanies isolated hypogonadotropic hypogonadism, either partially (hyposmia) or completely (anosmia), as determined by standardized quantitative testing or patient self-report (quantitative testing is far more accurate as up to 60% of “normosmic” patients by self-report have olfactory impairment when subjected to standardized testing) (45). Approximately two thirds of patients with isolated hypogonadotropic hypogonadism are classified as having Kallmann syndrome, with roughly one third each having anosmia or hyposmia (45). As mentioned earlier, many genetic etiologies can present as either isolated hypogonadotropic hypogonadism or Kallmann syndrome (eg, AXL, CHD7, DUSP6, FGF8, FGF17, FGFR1, FLRT3, HS6ST1, NSMF, PROKR2/PROK2, SPRY4, WDR11), whereas others present exclusively as Kallmann syndrome (ANOS1(KAL1), CCDC141, FEZF1, IL17RD, SEMA3A, SOX10) or exclusively as normosmic isolated hypogonadotropic hypogonadism (GNRH1, GNRHR, KISS1, KISS1R, SRA1, TACR3) (06). The severity of hypogonadism and loss of smell are not necessarily correlated in Kallmann syndrome: complete anosmia may be associated with partial gonadotropin deficiency (92; 23), and hyposmic patients with Kallmann syndrome can have some olfaction despite complete lack of secondary sex characteristics. Even in highly penetrant, genetically characterized forms of Kallmann syndrome, such as that due to ANOS1 variants, there can be variable degrees of olfactory impairment (52).

Despite the depressed production of gonadotropins in isolated hypogonadotropic hypogonadism, structural abnormalities of the pituitary gland or stalk have not been conclusively demonstrated or associated with specific genetic etiologies of isolated hypogonadotropic hypogonadism. Rather, early work and experts in reproductive endocrinology typically describe the pituitary gland as normal in patients with isolated hypogonadotropic hypogonadism (91; 06). A partially empty sella or small pituitary gland has been described in isolated case reports or in a minority of patients with isolated hypogonadotropic hypogonadism in some series (18; 79; 13). However, an actual statistical enrichment of this finding has not been demonstrated, and the precise radiographic criteria used in these studies are unclear. Additionally, it should be noted that a partially empty sella or small pituitary gland does not necessarily indicate depressed function (eg, incompetence of the diaphragma sella can be asymptomatic). Regardless of the true prevalence of pituitary hypoplasia in isolated hypogonadotropic hypogonadism, it should be acknowledged that some isolated hypogonadotropic hypogonadism genes have been implicated in morphologic abnormalities resembling septo-optic dysplasia, which does commonly have depressed pituitary volume (see below) and that pan-hypopituitarism has been described in a patient with a deficient pituitary stalk, ectopic posterior pituitary gland, and variants in both PROKR2 and WDR11 (55).

On the other hand, congenital structural abnormalities of the olfactory apparatus are common in Kallmann syndrome. Specifically, MRI abnormalities in the olfactory apparatus are reported in almost all anosmic patients and the vast majority of hyposmic patients (42; 45; 20; 79). The olfactory anomalies demonstrate a hierarchy of abnormality in that olfactory sulcus hypoplasia is typically only encountered in patients who also have olfactory bulb hypoplasia (79), and olfactory anomalies are asymmetric in as many as a half of the patients with Kallmann syndrome (95; 13). Because of the high penetrance of anosmia in ANOS1-related Kallmann syndrome, patients with this form of Kallmann syndrome almost always have olfactory anomalies (74; 45). Nonetheless, normal olfactory apparatus findings on imaging can be seen in as many as a third of hyposmic patients (45) and very rarely in anosmic patients also (20; 94). Perhaps even more perplexing, mild olfactory abnormalities (eg, unilateral bulb hypoplasia) have been reported in normosmic patients with isolated hypogonadotropic hypogonadism though the reported prevalence covers a wide range, from rare to a third of normosmic patients (91; 45; 20; 94).

Morphologic abnormalities and functional impairment can be seen outside of the hypothalamic-pituitary axis and olfactory apparatus in isolated hypogonadotropic hypogonadism and Kallmann syndrome. Of specific interest to neurologists, synkinesia (mirror movements) has been described in as many as 40% of patients with ANOS1-related Kallmann syndrome and a much smaller percentage of patients with FGFR1-related Kallmann syndrome (84). Structural abnormalities proposed to underlie the mirror movements include abnormal decussation of the corticospinal tracts and subtle alterations in gray matter distribution visible only after quantitative analysis (42; 50; 87). Additional neurologic symptoms reported in isolated hypogonadotropic hypogonadism include hearing loss in SOX10, IL17RD, and CHD7 (17; 56; 63), nystagmus in ANOS1 (84), focal dystonia of the lower limbs in a genetically uncharacterized patient (34), microphthalmia in a group of genetically uncharacterized patients with isolated hypogonadotropic hypogonadism (40; 44; 20), and intellectual disability in CHD7 (93; 46). Color blindness was a feature of Kallmann’s original patients, but a reliable association of this finding is difficult to locate in modern literature, especially in genetically ascertained cohorts (08).

On MRI, several structural abnormalities of the brain have been described in association with isolated hypogonadotropic hypogonadism. Dandy-Walker malformation or variant has been diagnosed in two unrelated teenage males (85; 03). Partial agenesis of the corpus callosum, white matter abnormalities resembling multiple sclerosis, and acoustic schwannoma have been reported in an older cohort of patients with Kallmann syndrome, though the degree to which these findings differ from the general population is unclear (49). Multiple papers have suggested an overlapping spectrum of neuroimaging findings in isolated hypogonadotropic hypogonadism, septo-optic dysplasia, and holoprosencephaly that blur classic genotype-phenotype relationships. This work includes cases of holoprosencephaly attributed to isolated hypogonadotropic hypogonadism genes, such as FGFR1, and mouse knock-out models of WDR11 (35; 28) as well as cases of isolated hypogonadotropic hypogonadism with variants in holoprosencephaly genes (86). Variants in septo-optic dysplasia genes, such as HESX1, have also been identified in isolated hypogonadotropic hypogonadism subjects (57; 15). Lastly, brain malformations associated with septo-optic dysplasia and midline anomalies more broadly (eg, schizencephaly, septal deficiency, optic nerve hypoplasia, callosal dysgenesis) have been found in individuals with variants in FGFR1 and PROKR2 (68; 54) though many of these variants are listed as “uncertain significance” or even benign in gnomAD (41). The validity of these associations awaits additional subjects and a better understanding of isolated hypogonadotropic hypogonadism genetics, especially instances of oligogenic inheritance.

Outside the nervous system, congenital anomalies reported in isolated hypogonadotropic hypogonadism include renal agenesis in ANOS1 (67) and cleft lip or palate and dental anomalies in FGF8 and FGFR1 (01; 64; 84; 05; 83; 90). In the case of CHD7, isolated hypogonadotropic hypogonadism can occur as part of the CHD7 disease spectrum (93; 46) with the suggestion that missense variants are more likely to produce isolated hypogonadotropic hypogonadism than CHARGE syndrome (51). Deficient nasal cartilage has been described in FGFR1-related isolated hypogonadotropic hypogonadism as well as in genetically unsolved cases (84; 20). Additional abnormalities described in isolated hypogonadotropic hypogonadism include thoracic cage anomalies (pectus excacatum), highly arched feet (pes cavus), and ichthyosis (43; 16; 20; 22). The sporadic appearance of femur-fibula-ulna dysostosis has been observed in one female patient with Kallmann syndrome (27). Although final height is typically normal in patients with isolated hypogonadotropic hypogonadism, arm span is typically increased due to delayed closure of epiphyses from the hypogonadism (66; 89).

Prognosis and complications

The effects of hypogonadism, namely delayed sexual maturation and infertility, are treatable (see treatment section below). However, there are several known comorbidities in isolated hypogonadotropic hypogonadism in addition to anosmia, some of which are treatment-related. Known comorbidities include increased fat mass and body mass index as well as osteopenia and insufficiency fractures (80; 44; 36; 04). The onset of testosterone therapy can also induce painful, low-flow priapism, which, in one case, required placement of a cavernous spongiosal shunt for relief (77). Finally, specific genetic causes of isolated hypogonadotropic hypogonadism are associated with nonendocrine co-morbidities, such as hearing loss, cleft lip or palate, hypodontia, and renal agenesis (06).

Biological basis

Etiology and pathogenesis

Although genetic testing still explains only half of the cases of isolated hypogonadotropic hypogonadism (48), the more than 25 genes implicated thus far fall into two general categories: (1) defects specific to gonadotropin-releasing hormone (GnRH) secretion or action and (2) defects in GnRH secreting neuron migration or specification (11; 06; 25). Alterations of genes in the first category cause isolated deficiency of gonadotropin-releasing hormone and, thus, normosmic isolated hypogonadotropic hypogonadism (eg, GNRH1 and GNRHR, GnRH and its cognate receptor). Alterations in the second category cause broader forebrain neuron deficiencies, resulting in either Kallmann syndrome only (eg, ANOS1, SOX10) or both Kallmann syndrome and normosmic isolated hypogonadotropic hypogonadism (eg, PROK2, PROKR2, WDR11).

The genetics of isolated hypogonadotropic hypogonadism are extremely complex, and the details are beyond the scope of this review (06). However, several points are worth emphasizing. First, even the most frequent genetic causes of isolated hypogonadotropic hypogonadism or Kallmann syndrome (eg, ANOS1, GNRHR, FGFR1) are individually rare, accounting for 5% to 10% of large populations of patients with isolated hypogonadotropic hypogonadism ascertained by specialty clinics, and the vast majority of genes explain no more than a few percent of isolated hypogonadotropic hypogonadism or Kallmann syndrome cases (06; 61). Second, ANOS1 is the only known isolated hypogonadotropic hypogonadism or Kallmann syndrome gene with X-linked inheritance, and ANOS1-related Kallmann syndrome is almost exclusively seen in males with near complete penetrance (48). Despite the theoretical possibility of breakthrough symptoms in ANOS1 females due to X-linked inactivation, ascertained populations of patients with Kallmann syndrome and isolated hypogonadotropic hypogonadism have demonstrated either no females (25) or the extremely rare hyposmic ANOS1 female (45). Third, the penetrance of autosomal recessive forms is fairly high, typically manifesting exclusively as normosmic isolated hypogonadotropic hypogonadism (eg, GNRHR, GNRH1, TAC3, TACR3) or Kallmann syndrome (eg, FEZF1). However, penetrance for heterozygous forms of isolated hypogonadotropic hypogonadism is more unpredictable with a range of endocrine and olfactory impairment (06). Fourth, virtually all known isolated hypogonadotropic hypogonadism genes have been found to demonstrate oligenic inheritance (48; 06). For example, PROKR2-related Kallmann syndrome has been seen in conjunction with variants in multiple other isolated hypogonadotropic hypogonadism genes, including ANOS1 (32), SEMA3A (29), WDR11 (55), and PROK2 (16).

Differential diagnosis

Confusing conditions

Although this review has focused on congenital hypogonadotropic hypogonadism, hypogonadotropic hypogonadism can also be caused by acquired conditions, including sellar or pituitary tumors (eg, prolactinoma), systemic conditions (eg, sarcoidosis, hemochromatosis), and trauma (07). Hypergonadotropic hypogonadism (also called primary hypogonadism) is readily distinguishable from isolated hypogonadotropic hypogonadism due to the appropriate elevation of gonadotropins in response to decreased sex hormone secretion by the gonads (81). Common causes for hypergonadotropic hypogonadism include genetic disorders (eg, Klinefelter syndrome) and acquired conditions more common to older patients (eg, trauma, chemotherapy, radiation).

Associated or underlying disorders

Hypogonadotropic hypogonadism can be seen in the setting of multisystem disorders, which are often omitted from discussions of isolated hypogonadotropic hypogonadism or can manifest as isolated hypogonadotropic hypogonadism as well as a broader disorder. For example, the so-called “4H” syndrome caused by pathogenic variants in POLR3A/POLR3B presents as a hypomyelinating leukodystrophy with hypodontia in addition to hypogonadotropic hypogonadism (09); POLR3B variants have also been reported as a cause of isolated hypogonadotropic hypogonadism (70). Similarly, CHD7-related disorders comprise a spectrum that includes Kallmann syndrome (93) and more complex presentations such as CHARGE syndrome (88). There are also more complex genetic conditions, such as RAB18 deficiency, where hypogonadotropic hypogonadism is just a part of a complex reproducible phenotype (30).

There is evidence of a spectrum of morphologic abnormalities that include septo-optic dysplasia, Kallmann syndrome, and holoprosencephaly. In this regard, it is important to recall that septo-optic dysplasia is ultimately a clinicoradiologic syndrome and need not necessarily have a deficiency of the septum pellucidum (78). With this in mind, it is perhaps unsurprising that a single gene, such as HESX1, can present as septo-optic dysplasia, combined pituitary hormone deficiency, or isolated hypogonadotropic hypogonadism (19; 82; 57; 24).

Isolated anatomic features of isolated hypogonadotropic hypogonadism or Kallmann syndrome can be seen in several genetic conditions that do not have hypogonadotropic hypogonadism. Micropenis can be observed in a variety of other syndromes (60). Absent olfactory bulbs and tracts are observed in a number of malformation complexes, including holoprosencephaly, or may be isolated. Some affected patients have abnormal karyotypes or Mendelian disorders (12; 02).

Diagnostic workup

Physical diagnosis and imaging. Because secondary sexual characteristics do not manifest until adolescence, isolated hypogonadotropic hypogonadism is generally difficult to detect earlier in life. However, one exception is the detection of micropenis and cryptorchidism, which occur in 15% and 29%, respectively, of male patients with isolated hypogonadotropic hypogonadism and are even more frequent in patients with Kallmann syndrome who have a more pronounced reproductive phenotype (65). Because of physiologic “mini-puberty” seen during neonatal life, males with isolated hypogonadotropic hypogonadism can be confirmed as having deficient sex hormone and gonadotropin during this period, opening a window for treatment with testosterone, gonadotropins, or pulsatile GnRH (14). In older patients, the key examination finding is delayed development of secondary sexual characteristics, usually defined as 2.5 standard deviations later than the population mean for sex. A working definition of delayed puberty is testicular volume less than 4 mL for a 14-year-old boy or lack of breast development by 13 years of age in a girl (59; 11). Pubic hair specifically is not a reliable indicator of hypogonadism because of adrenally sourced androgens. Differentiating isolated hypogonadotropic hypogonadism from constitutional delay in puberty may be difficult until late into adolescence in the absence of positive family history, co-occurring symptoms (eg, anosmia, renal agenesis), or positive genetic testing because constitutional delay and isolated hypogonadotropic hypogonadism have overlapping hormonal profiles (06). Although self-report of anosmia is generally accurate, a standardized testing instrument is far more accurate in detecting and quantifying the severity of olfactory impairment and should be implemented when isolated hypogonadotropic hypogonadism is raised as a diagnostic possibility (45).

Imaging can be a useful adjunct in the diagnosis of isolated hypogonadotropic hypogonadism. Specifically, olfactory apparatus hypoplasia is readily detected by brain MRI and can support the diagnosis of isolated hypogonadotropic hypogonadism or Kallmann syndrome more specifically. Additionally, brain MRI can be used to exclude other disorders that may potentially mimic isolated hypogonadotropic hypogonadism, such as brain tumors, mild forms of holoprosencephaly, and other findings suggestive of a syndromic diagnosis (eg, hypomyelination in “4H syndrome”). CT provides a better depiction of hypodontia but is unlikely to provide definitive information about the olfactory apparatus or the hypothalamus or pituitary gland. Renal ultrasound is another useful tool that may help build evidence of a genetic cause of isolated hypogonadotropic hypogonadism (eg, ANOS1-related renal agenesis) (39). Finally, it is worth noting that bone ages will typically be delayed in patients with isolated hypogonadotropic hypogonadism, though this is a nonspecific finding with myriad alternative medical explanations (59).

History. A careful history should be elicited with emphasis on pubertal signs and clues to syndromic causes of isolated hypogonadotropic hypogonadism (eg, impaired olfaction). Potential alternative explanations for hypogonadism should also be explored, including chronic medical illness, history of cancer, associated therapies, medications, and trauma (53; 81). Family history is also important for detecting inherited causes of isolated hypogonadotropic hypogonadism and also for differentiating isolated hypogonadotropic hypogonadism from constitutional delay in puberty (59).

Other morphological tests. Due to their invasive nature, biopsies are not a standard procedure in the workup and management of isolated hypogonadotropic hypogonadism. However, testicular biopsy has shown no evidence of sexual maturation in the complete form of isolated hypogonadotropic hypogonadism; interstitial fibrosis and decreased (type B) Sertoli and Leydig cell populations have been described (62). Conversely, some germinal cell maturation can be detected in milder isolated hypogonadotropic hypogonadism cases (58). Laparoscopy has also been employed to visualize hypoplastic internal female genitalia and to biopsy immature ovaries (27).

Endocrine studies. In the complete form of Kallmann syndrome, serum levels of testosterone, estrogen, follicle-stimulating hormone, and luteinizing hormone are low. However, these hormones and other serum markers do not reliably distinguish isolated hypogonadotropic hypogonadism from constitutional pubertal delay with any reliability (59; 07; 11).

Biochemical tests. In addition to endocrine studies, laboratory tests can also be performed to exclude alternative causes of hypogonadism (eg, hemochromatosis) (11).

Genetics. The genetics of isolated hypogonadotropic hypogonadism is complex due to there being more than 25 genes implicated thus far, a variety of inheritance patterns (X-linked recessive, autosomal dominant, autosomal recessive), evidence of oligenic inheritance for some genes, and incomplete penetrance.

Management

Management of isolated hypogonadotropic hypogonadism is directed at restoring normal sex hormone function through exogenous supplementation and enabling fertility for those patients desiring it. As mentioned earlier, preadolescent diagnosis of isolated hypogonadotropic hypogonadism is usually restricted to male neonates who normally experience “mini-puberty,” which facilitates diagnosis of gonadotropin deficiency. In these patients, testosterone or exogenous gonadotropin can be administered to increase penis size and to increase testicular volumes (14). For most patients, the diagnosis of isolated hypogonadotropic hypogonadism is made in adolescence, at which time exogenous sex steroids (ie, testosterone for males, estrogen later followed by cyclic progestin use for females) provide the most straightforward means of inducing secondary sexual characteristics (11). However, sex steroids alone are inadequate to induce gametogenesis and fertility, something that requires gonadotropin injection or pulsatile GnRH administration to simulate physiologic stimulation of the pituitary (06). Monitoring for complications of hormone replacement therapy (eg, erythrocytosis, hyperlipidemia from exogenous testosterone) and effects of hypogonadism (eg, osteopenia) may lead to a need for additional medical treatment (07; 11). Although sex steroids are generally required for the remainder of an isolated hypogonadotropic hypogonadism patient’s life, reversal of isolated hypogonadotropic hypogonadism (ie, acceleration in testicular growth and function) following cessation of testosterone therapy has been reported in up to 10% of men with isolated hypogonadotropic hypogonadism (69).

Outcomes

Overall differences in life expectancy have not been reported for isolated hypogonadotropic hypogonadism.

References

01: Albuisson J, Pecheux C, Carel JC, et al. Kallmann syndrome: 14 novel mutations in KAL1 and FGFR1 (KAL2). Hum Mutat 2005;25(1):98-9. PMID 15605412
02: Aleo S, Cinnante C, Avignone S, et al. Olfactory malformations in Mendelian disorders of the epigenetic machinery. Front Cell Dev Biol 2020;8:710. PMID 32850830
03: Aluclu MU, Bahceci S, Bahceci M. A rare embryological malformation of brain - Dandy-Walker syndrome - and its association with Kallmann’s syndrome. Neuro Endocrinol Lett 2007;28(3):255-8. PMID 17627258
04: Antonio L, Caerels S, Jardi F, Delaunay E, Vanderschueren D. Testosterone replacement in congenital hypogonadotropic hypogonadism maintains bone density but has only limited osteoanabolic effects. Andrology 2019;7(3):302-6. PMID 30851011
05: Bailleul-Forestier I, Gros C, Zenaty D, Bennaceur S, Leger J, de Roux N. Dental agenesis in Kallmann syndrome individuals with FGFR1 mutations. Int J Paediatr Dent 2010;20(4):305-12. PMID 20536592
06: Balasubramanian R, Crowley WF. Isolated gonadotropin-releasing hormone (GnRH) deficiency. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. Seattle, WA: GeneReviews®, 1993. Updated May 2022.**
07: Basaria S. Male hypogonadism. Lancet 2014;383(9924):1250-63. PMID 24119423
08: Benbassat CA. Kallmann syndrome: eugenics and the man behind the eponym. Rambam Maimonides Med J 2016;7(2):e0015. PMID 27101217
09: Bernard G, Vanderver A. POLR3-related leukodystrophy. In: Adam MP, Feldman J, Mirzaa GM, et al, editors. Seattle, WA: GeneReviews®, 1993. Updated May 2017.
10: Best LG, Wasdahl WA, Larson LM, Sturlaugson J. Chromosome abnormality in Kallmann syndrome. Am J Med Genet 1990;35:306-9. PMID 2309777
11: Boehm U, Bouloux PM, Dattani MT, et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 2015;11(9):547-64.** PMID 26194704
12: Booth TN, Rollins NK. Spectrum of clinical and associated MR imaging findings in children with olfactory anomalies. AJNR Am J Neuroradiol 2016;37(8):1541-8. PMID 26988815
13: Bortolotto Felippe Trentin M, Borges Daniel K, Reis F, et al. Reconsidering the olfactory and brain structures in Kallmann's syndrome: new findings in the analysis of volumetry. Clin Endocrinol (Oxf) 2023;98(4):554-8. PMID 36536529
14: Bouvattier C, Majone L, Bouligand J, et al. Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism. Nat Rev Endocrinol 2011;8:172-82. PMID 22009162
15: Ciftci N, Akıncı A, Akbulut E, et al. Clinical characteristics and genetic analyses of patients with idiopathic hypogonadotropic hypogonadism. J Clin Res Pediatr Endocrinol 2023;15(2):160-71. PMID 36700485
16: Cole LW, Sidis Y, Zhang C, et al. Mutations in prokineticin 2 and prokineticin receptor 2 genes in human gonadotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum. J Clin Endocrinol Metab 2008;93(9):3551-9. PMID 18559922
17: Costa-Barbosa FA, Balasubramanian R, Keefe KW, et al. Prioritizing genetic testing in patients with Kallmann syndrome using clinical phenotypes. J Clin Endocrinol Metab 2013;98(5):E943-53. PMID 23533228
18: Dallago CM, Abech DD, Pereira-Lima JF, et al. Two cases of Kallmann syndrome associated with empty sella. Pituitary 2008;11(1):109-12. PMID 17530415
19: Dattani MT, Martinez-Barbera JP, Thomas PQ, et al. Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet 1998;19(2):125-33. PMID 9620767
20: Della Valle E, Vezzani S, Rochira V, et al. Prevalence of olfactory and other developmental anomalies in patients with central hypogonadotropic hypogonadism. Front Endocrinol (Lausanne) 2013;4:70. PMID 23760293
21: DeMorsier G. Études sur les dysraphies crânioencéphaliques. 1 Agénésie des lobes olfactifs (télencéphaloschizis latéral) et des commissures calleuse et antérieure (télencéphaloschizis médian). La dysplasie olfactogénitale. Schweiz Arch Neurol Psychiatr 1954;74:309-61.
22: Dwyer AA, Stamou MI, Anghel E, et al. Reproductive phenotypes and genotypes in men with IHH. J Clin Endocrinol Metab 2023;108(4):897-908. PMID 36268624
23: Dwyer AA, Stamou M, McDonald IR, et al. Reversible hypogonadotropic hypogonadism in men with the fertile eunuch/Pasqualini syndrome: a single-center natural history study. Front Endocrinol (Lausanne) 2022;13:1054447. PMID 36407308
24: Fang Q, Benedetti AF, Ma Q, et al. HESX1 mutations in patients with congenital hypopituitarism: variable phenotypes with the same genotype. Clin Endocrinol (Oxf) 2016;85(3):408-14. PMID 27000987
25: Federici S, Cangiano B, Goggi G, et al. Genetic and phenotypic differences between sexes in congenital hypogonadotropic hypogonadism (CHH): large cohort analysis from a single tertiary centre. Front Endocrinol (Lausanne) 2022;13:965074. PMID 36531499
26: Gao Y, Yu B, Mao J, Wang X, Nie M, Wu X. Assisted reproductive techniques with congenital hypogonadotropic hypogonadism patients: a systematic review and meta-analysis. BMC Endocr Disord 2018;18(1):85. PMID 30453944
27: Gasztonyi Z, Barsi P, Czeizel AE. Kallmann syndrome in three unrelated women and an association with femur-fibula-ulna dysostosis in one case. Am J Med Genet 2000;93(3):176-80. PMID 10925376
28: Haag N, Tan EC, Begemann M, et al. Biallelic loss-of-function variants in WDR11 are associated with microcephaly and intellectual disability. Eur J Hum Genet 2021;29(11):1663-8. PMID 34413497
29: Hanchate NK, Giacobini P, Lhuillier P, et al. SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with Kallmann syndrome. PLoS Genet 2012;8(8):e1002896. PMID 22927827
30: Handley M, Sheridan E. RAB18 deficiency. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. Seattle, WA: GeneReviews®, 1993. Updated January 2018.
31: Hardelin JP. Kallmann syndrome: towards molecular pathogenesis. Mol Cell Endocrinol 2001;179:75-81. PMID 11420131
32: Hardelin JP, Dode C. The complex genetics of Kallmann syndrome: KAL1, FGFR1, FGF8, PROKR2, PROK2, et al. Sex Dev 2008;2(4-5):181-93. PMID 18987492
33: Hayes FJ, Seminara SB, Crowley WF. Hypogonadotropic hypogonadism. Endocrinol Metab Clin North Am 1998;27(4):739-63. PMID 9922906
34: Hernando-Quintana N, Playán-Usón J, Crespo-Burillo JA, Marín-Cárdenas MÁ, Gazulla J. Ataxia and focal dystonia in Kallmann syndrome. Clin Case Rep 2015;4(2):182-5. PMID 26862419
35: Hong S, Hu P, Marino J, et al. Dominant-negative kinase domain mutations in FGFR1 can explain the clinical severity of Hartsfield syndrome. Hum Mol Genet 2016;25(10):1912-22. PMID 26931467
36: Iolascon G, Frizzi L, Bianco M, et al. Bone involvement in males with Kallmann disease. Aging Clin Exp Res 2015;Suppl 1:S31-6. PMID 26201943
37: Jindal UN, Jindal S. Ovulation induction in hypogonadotropic hypogonadism. In: Ghumman S, editor. Principles and Practice of Controlled Ovarian Stimulation in ART. India: Springer, 2015:357-68.
38: Kallmann F, Schoenfeld WA, Barrera SE. The genetic aspects of primary eunuchoidism. Am J Ment Defic 1944;48:203-36.
39: Kaplan JD, Bernstein JA, Kwan A, Hudgins L. Clues to an early diagnosis of Kallmann syndrome. Am J Med Genet A 2010;152A(11):2796-801. PMID 20949504
40: Keppen LD, Brodsky MC, Michael JM, Poindexter AR. Hypogonadotropic hypogonadism in mentally retarded adults with microphthalmia and clinical anophthalmia. Am J Med Genet 1990;36(3):285-7. PMID 2363423
41: Koch L. Exploring human genomic diversity with gnomAD. Nat Rev Genet 2020;21(8):448. PMID 32488197
42: Koenigkam-Santos M, Santos AC, Borduqui T, et al. Whole-brain voxel-based morphometry in Kallmann syndrome associated with mirror movements. Am J Neuroradiol 2008;29:1799-804. PMID 18768731
43: Krishnamurthy S, Kapoor S, Yadav S. Nephrotic syndrome with X-linked ichthyosis, Kallmann Syndrome and unilateral renal agenesis. Indian Pediatr 2007;44(4):301-3. PMID 17468528
44: Laitinen EM, Hero M, Vaaralahti K, et al. Bone mineral density, body composition and bone turnover in patients with congenital hypogonadotropic hypogonadism. Int J Androl 2012;35(4):535-40. PMID 22248317
45: Lewkowitz-Shpuntoff HM, Hughes VA, Plummer L, et al. Olfactory phenotypic spectrum in idiopathic hypogonadotropic hypogonadism: pathophysiological and genetic implications. J Clin Endocrinol Metal 2012;97:E136-44. PMID 22072740
46: Li JD, Wu J, Zhao Y, et al. Phenotypic spectrum of idiopathic hypogonadotropic hypogonadism patients with CHD7 variants from a large Chinese cohort. J Clin Endocrinol Metab 2020;105(5):dgz182. PMID 31689711
47: Liu Y, Zhi X. Advances in genetic diagnosis of Kallmann syndrome and genetic interruption. Reprod Sci 2022;29(6):1697-709. PMID 3423117
48: Maione L, Dwyer AA, Francou B, et al. Genetics in endocrinology: Genetic counseling for congenital hypogonadotropic hypogonadism and Kallmann syndrome: new challenges in the era of oligogenism and next-generation sequencing. Eur J Endocrinol 2018;178(3):R55-R80. PMID 29330225
49: Manara R, Salvalaggio A, Favaro A, et al. Brain changes in Kallmann syndrome. AJNR Am J Neuroradiol 2014;35(9):1700-6. PMID 24788131
50: Manara R, Salvalaggio A, Citton V, et al. Brain anatomical substrates of mirror movements in Kallmann syndrome. Neuroimage 2015;104:52-8. PMID 25300200
51: Marcos S, Sarfati J, Leroy C, et al. The prevalence of CHD7 missense versus truncating mutations is higher in patients with Kallmann syndrome than in typical CHARGE patients. J Clin Endocrinol Metab 2014;99(10):E2138-43. PMID 25077900
52: Massin N, Pecheux C, Eloit C, et al. X chromosome-linked Kallmann syndrome: clinical heterogeneity in three siblings carrying an intragenic deletion of the KAL-1 gene. J Clin Endocrinol Metal 2003;88:2003-8. PMID 12727945
53: McCabe MJ, Bancalari RE, Dattani MT. Diagnosis and evaluation of hypogonadism. Pediatr Endocrinol Rev 2014;Suppl 2:214-29. PMID 24683946
54: McCabe MJ, Gaston-Massuet C, Gregory LC, et al. Variations in PROKR2, but not PROK2, are associated with hypopituitarism and septo-optic dysplasia. J Clin Endocrinol Metab 2013;98(3):E547-57. PMID 23386640
55: McCormack SE, Li D, Kim YJ, et al. Digenic inheritance of PROKR2 and WDR11 mutations in pituitary stalk interruption syndrome. J Clin Endocrinol Metab 2017;102(7):2501-7. PMID 28453858
56: Miraoui H, Dwyer AA, Sykiotis GP, et al. Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism. Am J Hum Genet 2013;92(5):725-43. PMID 23643382
57: Newbern K, Natrajan N, Kim HG, et al. Identification of HESX1 mutations in Kallmann syndrome. Fertil Steril 2013;99(7):1831-7. PMID 23465708
58: Nishio H, Mizuno K, Moritoki Y, et al. Clinical features and testicular morphology in patients with Kallmann syndrome. Urology 2012;79:684-6. PMID 22173178
59: Palmert MR, Dunkel L. Clinical practice: delayed puberty. N Engl J Med 2012;366(5):443-53. PMID 22296078
60: Parisi MA, Kletter GB, Grady R, et al. Micropenis with testicular regression, low LH levels, and poor androgen and HCG responses: a distinct syndrome. Am J Med Genet 2002;109:271-7. PMID 11992480
61: Patil VA, Lila AR, Shah N, et al. Genetic spectrum of Kallmann syndrome: single-center experience and systematic review. Clin Endocrinol (Oxf) 2022;97(6):804-13. PMID 36138264
62: Pervaiz N, Hagedoorn J, Mininberg DT. Electron microscopic studies of testes in Kallmann syndrome. Urology 1979;14:267-9. PMID 39377
63: Pingault V, Bodereau V, Baral V, et al. Loss-of-function mutations in SOX10 cause Kallmann syndrome with deafness. Am J Hum Genet 2013;92(5):707-24. PMID 23643381
64: Pitteloud N, Acierno JS Jr, Meysing A, et al. Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci UWA 2006;103:6281-6. PMID 16606836
65: Pitteloud N, Hayes FJ, Boepple PA, et al. The role of prior pubertal development, biochemical markers of testicular maturation, and genetics in elucidating the phenotypic heterogeneity of idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2002;87:152-60. PMID 11788640
66: Plymate S. Hypogonadism. Endocrinol Metab Clin North Am 1994;23(4):749-72. PMID 7705318
67: Quinton R, Duke VM, Robertson A, et al. Idiopathic gonadotrophin deficiency: genetic questions addressed through phenotypic characterization. Clin Endocrinol (Oxf) 2001;55(2):163-74. PMID 11531922
68: Raivio T, Avbelj M, McCabe MJ, et al. Genetic overlap in Kallmann syndrome, combined pituitary hormone deficiency, and septo-optic dysplasia. J Clin Endocrinol Metal 2012;97:E694-9. PMID 22319038
69: Raivio T, Falardeau J, Dwyer A, et al. Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med 2007;357(9):863-73. PMID 17761590
70: Richards MR, Plummer L, Chan YM, et al. Phenotypic spectrum of POLR3B mutations: isolated hypogonadotropic hypogonadism without neurological or dental anomalies. J Med Genet 2017;54(1):19-25. PMID 27512013
71: Rogol AD, Mittal KK, White BJ, et al. HLA-compatible paternity in two "fertile eunuchs" with congenital hypogonadotropic hypogonadism and anosmia (the Kallmann syndrome). J Clin Endocrinol Metab 1980;51(2):275-9. PMID 6772660
72: Rugarli EI, Ballabio A. Kallmann syndrome: from genetics to neurobiology. JAMA 1993;270:2713-6. PMID 8133589
73: Salenave S, Chanson P, Bry H, et al. Kallmann’s syndrome: a comparison of the reproductive phenotypes in men carrying KAL1 and FGFR1/KAL2 mutations. J Clin Endocrinol Metab 2008;93(3):758-63. PMID 18160472
74: Sato N, Katsumata N, Kagami M, et al. Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients. J Clin Endocrinol Metab 2004;89(3):1079-88. PMID 15001591
75: Sato N, Ohyama K, Fukami M, Okada M, Ogata T. Kallmann syndrome: somatic and germline mutations of the fibroblast growth factor receptor 1 gene in a mother and the son. J Clin Endocrinol Metab 2006;91:1415-8. PMID 16418210
76: Shaw ND, Seminara SB, Welt CK, et al. Expanding the phenotype and genotype of female GnRH deficiency. J Clin Endocrinol Metab 2011;96(3):E566-76. PMID 21209029
77: Shergill IS, Pranesh N, Hamid R, et al. Testosterone induced priapism in Kallmann’s syndrome. J Urol 2003;169:1089. PMID 12576857
78: Signorini SG, Decio A, Fedeli C, et al. Septo-optic dysplasia in childhood: the neurological, cognitive and neuro-ophthalmological perspective. Dev Med Child Neurol 2012;54(11):1018-24. PMID 22924461
79: Tang RY, Chen R, Ma M, Lin SQ, Zhang YW, Wang YP. Clinical characteristics of 138 Chinese female patients with idiopathic hypogonadotropic hypogonadism. Endocr Connect 2017;6(8):800-10. PMID 29018155
80: Taylor HS, Cass I, Lang R. Bone loss in Kallmann syndrome. Obstet Gynecol 1996;88:734. PMID 8841280
81: Thirumalai A, Anawalt BD. Epidemiology of male hypogonadism. Endocrinol Metab Clin North Am 2022;51(1):1-27. PMID 35216709
82: Thomas PQ, Dattani MT, Brickman JM, et al. Heterozygous HESX1 mutations associated with isolated congenital pituitary hypoplasia and septo-optic dysplasia. Hum Mol Genet 2001;10(1):39-45. PMID 11136712
83: Trarbach EB, Abreu AP, Silveira LF, et al. Nonsense mutations in FGF8 gene causing different degrees of human gonadotropin-releasing deficiency. J Clin Endocrinol Metab 2010;95(7):3491-6. PMID 20463092
84: Tsai PS, Gill JC. Mechanisms of disease: Insights into X-linked and autosomal-dominant Kallmann syndrome. Nat Clin Pract Endocrinol Metab 2006;2(3):160-71. PMID 16932275
85: Ueno H, Yamaguchi H, Katakami H, Matsukura S. A case of Kallmann syndrome associated with Dandy-Walker malformation. Exp Clin Endocrinol Diabetes 2004;112(1):62-7. PMID 14758574
86: Vaaralahti K, Raivio T, Koivu R, Valanne L, Laitinen EM, Tommiska J. Genetic Overlap between holoprosencephaly and Kallmann Syndrome. Mol Syndromol 2012;3(1):1-5. PMID 22855648
87: Vale TC, Pedroso JL, Rivero RL, et al. Lack of decussation of pyramids in Kallmann syndrome presenting with mirror movements. J Neurol Sci 2017;372:220-22. PMID 28017217
88: van Ravenswaaij-Arts CM, Hefner M, Blake K, Martin DM. CHD7 disorder. In: Adam MP, Feldman J, Mirzaa GM, editors. Seattle, WA: GeneReviews®, 1993. Updated September 2022
89: Varimo T, Hero M, Laitinen EM, et al. Childhood growth in boys with congenital hypogonadotropic hypogonadism. Pediatr Res 2016;79(5):705-9. PMID 26720605
90: Villanueva C, de Roux N. FGFR1 Mutations in Kallmann Syndrome. Front Horm Res 2010;39:51-61. PMID 20389085
91: Vogl TJ, Stemmler J, Heye B, et al. Kallmann syndrome versus idiopathic hypogonadotropic hypogonadism at MR imaging. Radiology 1994;191:53-7. PMID 8134597
92: Wortsman J, Hughes LF. Case report: olfactory function in a fertile eunuch with Kallmann syndrome. Am J Med Sci 1996;311:135-8. PMID 8615388
93: Xu C, Cassatella D, van der Sloot AM, etal. Evaluating CHARGE syndrome in congenital hypogonadotropic hypogonadism patients harboring CHD7 variants. Genet Med 2018;20(8):872-81. PMID 29144511
94: Yu B, Chen K, Mao J, et al. The diagnostic value of the olfactory evaluation for congenital hypogonadotropic hypogonadism. Front Endocrinol (Lausanne) 2022;13:909623. PMID 36187095
95: Zhang Z, Sun X, Wang C, Zhao B. Magnetic resonance imaging findings in Kallmann syndrome: 14 cases and review of the literature. J Comput Assist Tomogr 2016;40(1):39-42. PMID 26571055

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Edward Yang MD PhD

Dr. Yang of Boston Children's Hospital and Harvard Medical School received academic funds from Syngeos for service on a clinical trial and a consulting fee from Realta Life Sciences.
See Profile

Editor

Ganeshwaran H Mochida MD

Dr. Mochida of Boston Children's Hospital and Harvard Medical School has no relevant financial relationships to disclose.
See Profile

Former Authors

Joseph R Siebert PhD

Patient Profile

Age range of presentation: 0 month to 44 years
Sex preponderance: male>female,>2:1
Heredity: autosomal dominant

autosomal recessive

X-linked
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Kallmann syndrome: 253.4
ICD-10: Kallmann syndrome: E23.0
OMIM: Kallmann syndrome 1: +308700

Kallmann syndrome 2: #147950

Kallmann syndrome 3: #244200

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Isolated hypogonadotropic hypogonadism

Associated Disorders

Anosmia
Arhinencephaly
CHARGE
Choanal atresia
Cleft lip
- Cleft palate
- Color blindness
- Dandy-Walker malformation
- Dandy-Walker variant
- Holoprosencephaly
- Hypogonadism
- Hyposmia
- Ichthyosis
- Neuronal migration defect
- Renal agenesis

Differential Diagnosis

holoprosencephaly
normosmic idiopathic hypogonadotropic hypogonadism
adult-onset hypogonadotropic hypogonadism
Perrin syndrome
Johnson syndrome
- Varadi syndrome
- Fitch syndrome
- anosmia
- radiohumeral synostosis syndrome
- campomelic dysplasia
- CHARGE syndrome
- CHARGE association
- combined pituitary hormone deficiency (panhypopituitarism)
- schizophrenia
- familial anosmia

Also Relevant

Olfactory hypoplasias and agenesis
Molecular diagnosis of neurogenetic disorders

Clinical Categories

Developmental Malformations

Web References

Testing

Kallmann Syndrome 2

Clinical Trials

NIH: Kallmann Syndrome

Isolated hypogonadotropic hypogonadism …

Isolated hypogonadotropic hypogonadism

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

X-linked hydrocephalus (L1 syndrome)

Cerebro-oculo-facio-skeletal syndrome

Schizencephaly

Fetal anticonvulsant syndrome

Rhombencephalosynapsis

Malformations of the brain

Von Hippel-Lindau disease

Vein of Galen malformations

Isolated hypogonadotropic hypogonadism

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

X-linked hydrocephalus (L1 syndrome)

Cerebro-oculo-facio-skeletal syndrome

Schizencephaly

Fetal anticonvulsant syndrome

Rhombencephalosynapsis

Malformations of the brain

Von Hippel-Lindau disease

Vein of Galen malformations

This is an article preview.
Start a Free Account
to access the full version.